GermanyGermany

Wilex finds US commercialisation partner for Rencarex

03.05.2011

Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.

GermanyGermany

16.08.2011

Berlin – Despite intense marketing measures, revenues from Epigenomics’ Epi proColon bowel cancer test remain flat. Along with its QII/2011 numbers, the Berlin-based in vitro diagnostic specialist revealed strict cost-saving...

GermanyGermany

05.08.2011

Boehringer Ingelheim is the first around the post. The European Commission cleared the German company's oral anticoagulant Pradaxa (dabigatran etexilate) for preventing stroke in atrial fibrillation patients at risk of stroke....

GermanyGermany

27.07.2011

Berlin – Reprogramming fibroblasts into human induced pluripotent stem cells (hiPSCs) can cause mitochondrial diseases, according to two reseearch groups from Berlin-based Max Planck Institute for Molecular Genetics. In every...

Germany, UKGermany

21.07.2011

In a first for European drug research, scientists have launched a clinical trial of an anti-HIV biotech medicine produced using genetically modified tobacco. Transgenic tobacco plants are grown for 45 days before being processed...

Germany, SwitzerlandGermany

19.07.2011

Basel - Roche goes shopping in Germany. The Swiss pharmaceutical giant agreed to buy privately-held mtm laboratories, a specialist in diagnostics for detecting cervical cancer based in Heidelberg, for up to 190 million...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

Displaying results 31 to 40 out of 454

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/3/article/wilex-finds-us-commercialisation-partner-for-rencarex.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3457.6%
  • GW PHARMACEUTICALS (UK)419.75 GBP715.0%
  • PAION (D)2.77 EUR313.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 27.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products